Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 21 Nov 2017
At a glance
- Drugs Semaglutide (Primary) ; Liraglutide
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms PIONEER 9
- Sponsors Novo Nordisk
- 21 Nov 2017 According to a Novo Nordisk media release, the trial is expected to be completed in 2018.
- 21 Jun 2017 Status changed from recruiting to active, no longer recruiting.
- 18 Jan 2017 Status changed from not yet recruiting to recruiting.